GSK - Pharma Boss Aims For 14% Returns On Late Stage Pipeline
LONDON, February 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline today said it had posted a strong performance in a challenging year with a return to sales growth for the first time since 2007.
In an interview on http://www.cantos.com CEO Andrew Witty also announced a reduction in the investment into treatments for pain and depression and a restructuring of R&D.
He said:
"Now obviously I don't like to see anybody leave the organisation or there to be any job losses. But the reality is that we do, from time to time, need to look at ways in which we can improve our probability of success."
The interview and transcript are available now on http://www.cantos.com.
Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.
SOURCE GlaxoSmithKline
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article